Decreased DNA Methylation in the Shati/Nat8l Promoter in Both Patients with Schizophrenia and a Methamphetamine-Induced Murine Model of Schizophrenia-Like Phenotype

Abstract

The number of patients with schizophrenia has increased over the past decade. Previously, many studies have been performed to establish its diagnostic criteria, prophylactic methods, and effective therapies. In this study, we analyzed whether the ratios of DNA methylation in CpG islands of the Shati/Nat8l is decreased in model mice of schizophrenia-like phenotype using genomic DNA collected from brain regions and peripheral blood, since the mouse model of schizophrenia-like phenotype, mice treated repeatedly with methamphetamine showed increase of Shati/Nat8l mRNA expression in our previous experiment. The ratios of Shati/Nat8l CpG island methylation were significantly decreased in both the nucleus accumbens and the peripheral blood of model mice compared with those of control mice. We also investigated Shati/Nat8l methylation in the blood of patients with schizophrenia. We found that Shati/Nat8l CpG island methylation ratios were lower in the patients with schizophrenia than in the healthy controls, which is consistent with our findings in the mice model. To our knowledge, this is the first study to show similar alterations in methylation status of a particular genomic DNA site in both the brain and peripheral blood of mice. Furthermore, the same phenomenon was observed in corresponding human genomic sequences of the DNA extracted from the peripheral blood of patients with schizophrenia. Based on our findings, DNA methylation profiles of the CpG island of Shati/Nat8l might be a diagnostic biomarker of schizophrenia.

About the Authors:

Kyosuke Uno

Affiliation: Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan

Yuu Kikuchi

Affiliation: Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan

Mina Iwata

Affiliation: Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan

Takashi Uehara

Affiliation: Department of Neuropsychiatry, Kanazawa Medical University, Kahoku, Japan

Tadasu Matsuoka

Affiliations Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan, Medical Corporation Syoufukai, Matsuoka Hospital, Oyabe, Japan

Tomiki Sumiyoshi

Affiliations Department of Neuropsychiatry, University of Toyama Graduate School of Medicine and Pharmaceutical Sciences, Toyama, Japan, Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan

Yoshinori Okamoto

Affiliation: Faculty of Pharmacy, Meijo University, Nagoya, Japan

Hideto Jinno

Affiliation: Faculty of Pharmacy, Meijo University, Nagoya, Japan

Tatsuyuki Takada

Affiliation: Department of Pharmaceutical Sciences, Ritsumeikan University, Kusatsu, Japan

Yoko Furukawa-Hibi

Affiliation: Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, Nagoya, Japan

Toshitaka Nabeshima

Affiliation: Advanced Diagnostic System Research Laboratory, Fujita Health University, Graduate School of Health Sciences & Aino University, Toyoake & Ibaragi, Japan

Yoshiaki Miyamoto

Affiliation: Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan

Atsumi Nitta

* E-mail: [email protected]

Affiliation: Department of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan

ORCID http://orcid.org/0000-0001-6916-9160

Introduction

In recent years, the number of patients diagnosed with schizophrenia has increased in many countries. Previously, many studies have been performed to improve its prophylaxis, diagnosis, and treatment. Long-term medical treatments are required for these patients; however, due to the lack of accurate laboratory tests, early diagnosis of schizophrenia has not been possible. Currently, several psychiatric diseases, including schizophrenia, are diagnosed primarily through a diagnostic interview and/or an imaging analysis. Given that many patients lack subjective symptoms during the early stage of schizophrenia, it is uncommon for them to be referred to a psychiatric specialist, which is necessary for an early diagnosis. In psychiatric diseases, many changes occur in the brain. For example, it has been reported that SOX10 [1] and monoamine oxidase A and B [2] were methylated to a greater extent in the postmortem brains of patients with schizophrenia than in healthy controls. These results cannot be directly applied to the diagnosis of psychiatric diseases because obtaining a tissue sample from the brains of living patients is not feasible for the analysis of methylation status.

In this study, we focused on Shati/Nat8l as a potential genetic marker associated with psychiatric diseases. The expression of Shati/Nat8l was significantly increased in the nucleus accumbens (NAc) of mice treated with methamphetamine (Meth), which disrupts the formation of drug dependence [3–6]. It has been pointed out that a schizophrenia-like symptom has been observed in both mice and humans who have received chronic Meth treatment [7–9]. Therefore, we believe that Shati/Nat8l could be associated with psychiatric diseases, which can serve as a diagnostic marker. However, it is too difficult to measure its mRNA or protein levels in the brains of living patients within the traditional clinical setting.

With respect to cancer biology, epigenetic changes, without concomitant changes to genomic sequences, are an important factor for the understanding of mechanisms of cancer onset [10], which may serve as diagnostic markers. Some studies have indicated the possibility of applying epigenetic strategies to psychiatric diseases [11, 12]. One important component of epigenetics is DNA methylation, which is particularly found in the cytosine residues of the CpG (5'-CG-3') arrangement in DNA [13]. Domains that include large amounts of CpG have been termed as CpG Island (CpG Is). CpG Is is usually the upstream sites of the transcription initiation site where methylation takes place [14]. It is generally considered that transcription decreases when there is a higher amount of DNA methylation.

In this study, we focused on DNA methylation of Shati/Nat8l and analyzed the methylation ratio in CpG Is upstream of the Shati/Nat8l transcription start site, since the expression of Shati/Nat8l was increased in the NAc of mice treated with Meth [3]

Materials and Methods

Animals and Meth treatment

All experiments were performed on 8-week old male C57BL/6J inbred mice weighing about 20–25 g that were acquired from Nihon SLC Inc., Japan (Shizuoka, Japan). Mice were kept in a temperature and humidity-controlled environment with 12 h light/dark cycle (lights on at 8:00) and had access to food and water ad libitum. All mice received repeated treatment of methamphetamine were quickly decapitated by animal guillotine without feeling any suffering, since the fresh brain tissues were needed for the isolation of genomic DNA. This procedure were done without anesthesia to avoid the effect of anesthetic drugs. All procedures followed the National Institute of Health Guideline for the Care and Use of Laboratory Animals and were approved by the committee for Animal Experiments of the University of Toyama (Permit Number A2012-PHA31).

Mice were administered with saline or Meth hydrochloride (Dainippon Sumitomo Pharmaceutical Co, Osaka, Japan) at a dosage of 1 mg/kg for 6 days and decapitated 2 h after the last administration of Meth for bisulfate sequencing and quantitative real-time RT-PCR.

Quantitative RT-PCR

Quantitative RT-PCR was performed according to the previous reports [5]. Briefly, total RNA extraction was performed using ISOGEN-LS (NIPPON GENE, Tokyo, Japan). Total RNA from the brain tissues of mice were transcribed into cDNA using the Prime Script RT reagent kit (Takara, Shiga, Japan) according to the manufacturer’s recommendation. Real-time PCR was performed with SYBR Green-based reagents (Thunder Bird SYBR qPCR Mix, Toyobo, Tokyo, Japan), using a Takara Dice Real Time System (Takara). The reaction was performed as follows: 1 cycle at 95°C for 5 min; 45 cycles at 95°C for 20 s, 60°C for 20 s, and 72°C for 20 s. Primer sequences used for PCR were as follows: 5′-GTGATTCTGGCCTACCTGGA-3′ and 5′-CCACTGTGTTGTCCTCCTCA-3′ as mouse Shati/Nat8l primers (up and down), 5′-ACCCTGAAGTGCTCGACATC-3′ and 5′-AGGAAGGCCTTGACCTTTTC-3′ as mouse 36B4 primers (up and down).

Isolation of Genomic DNA

Genomic DNA from the brain was isolated using Extract-N-Amp Tissue PCR Kit (Sigma-Aldrich, St. Louis, MO) according to the manufacturer’s instructions. Genomic DNA from cardiac blood was isolated using Gentra Puregene Blood Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions.

Bisulfite Conversion

DNA (1 μg) was treated with sodium bisulfite using an EZ DNA Methylation Kit (Zymo Research, Orange, CA) according to the manufacturer’s instructions. Briefly, DNA, bisulfite mix, and DNA protect buffer were mixed together. The bisulfite conversion thermal cycling conditions were as follows: 99°C for 5 min, 60°C for 25 min, 99°C for 5 min, 60°C for 85 min, 99°C for 5 min, and 60°C for 175 min. Finally, the bisulfite-converted DNA was purified on a spin column and eluted with 20 μL of elution buffer.

Amplification of PCR Product

PCR primers were designed using Methyl Primer Express Software v1.0 (Applied Biosystems Inc., Foster City, CA https://products.appliedbiosystems.com/ab/en/US/adirect/ab?cmd=catNavigate2&catID=602121&tab=Overvie). PCR primer sets included sense (5′-GGGATTTAGGAGAAGTTAATGTG-3′) and antisense (5′-ACATATCCACTTTCCTAAATCACA-3′) primers. Thermal cycling conditions were as follows: 1 cycle at 94°C for 5 min, 35 cycles at 98°C for 30s, 57°C for 1 min, and 72°C for 2 min, 1 cycle at 72°C for 10 min.

Ligation, Transformation, and Sequence

PCR products were inserted into a pGEM-T Easy Vector System I (Promega, Madison, WI) by Ligation high ver. 2 (Toyobo, Osaka, Japan) according to the manufacturer’s instructions. Colonies were picked and cultured overnight in LB medium containing 50 μg/mL ampicillin. We isolated the plasmid DNA using a boiling mini-prep method, and the sequence was analyzed using both the T7 primer forward and reverse sequencing primers.

Sequence Analysis

DNA sequencing was performed with a BigDye terminator v1.1 cycle sequencing kit (Applied Biosystems Inc.) according to the manufacturer’s instructions. The T7 sequencing primer (Invitrogen, Carlsbad, CA, USA) and the sense primer 5′-TAATACGACTCACTATAGGG-3′ were used. The DNA-sequencing reactions in 96 well plates were run on a 3130 genetic analyzer (Applied Biosystems Inc.), and the resulting sequences were analyzed with sequencing analysis software (Applied Biosystems Inc.).

The Human Genomic Methylation Experiments

Seven Japanese schizophrenia male patients and seven healthy male volunteers were recruited from the outpatient unit of The University of Toyama Hospital. The clinical study protocol was conducted in accordance with the Declaration of Helsinki and its Amendments, and was approved by the institutional review board at the University of Toyama (Permit Number 24–6). Written informed consent was obtained from all the participants. Genomic DNA were collected from blood. Genomic DNA isolation and bisulfate sequence was performed as mentioned above. PCR primer for cloning into pGEM-T easy was as follows: human Shati/Nat8l up primer as 5′-GGAGTTATGTGGGATTTTTAAAGA-3′ and human Shati/Nat8l down primer as 5′-ACCTAACCCCCTTCAATTCTAC-3′.

Statistical Analysis

All data for mice are displayed as the mean ± SEM. Statistical differences between the two groups were determined with a Student’s-t test. In human methylation analysis, two groups were determined with an F test, followed by Student’s-t test.

Results

Shati/Nat8l mRNA expression in the NAc was increased in model mice of schizophrenia-like phenotype induced by repeated Meth administration

To confirm our previous results [3], we determined which brain regions show Shati/Nat8l mRNA upregulation by repeated administration of Meth to the mice. Shati/Nat8l mRNA expression was increased by the repeated administration of Meth (1 mg/kg for 6 days, s.c.) in the NAc (Fig 1a) 138.12 ± 6.36%, p < 0.05) but not in the hippocampus (HIP) (Fig 1b) (95.99 ± 10.09%) or the cerebellum (CB) (Fig 1c) (92.52 ± 8.08%). These findings were consistent with our previous report [3].

[Figure omitted. See PDF.]

Fig 1. Relative expression of Shati/Nat8l mRNA in mice administered saline or Meth.

Real-time RT-PCR was performed to quantify Shati/Nat8l mRNA in mice treated with saline (white bar) or MAP (black bar) from (a) nucleus accumbens (NAc), (b) hippocampus (HIP) and (c) cerebellum (CB). Primers used for each PCR are shown in the text. Data were normalized to 36B4 expression. The fold-change in expression of Shati/Nat8l mRNA was calculated using the ΔΔCT method. Data were plotted as the mean ± SEM. n = 6–8 mice. Significance is set at *p < 0.01.

https://doi.org/10.1371/journal.pone.0157959.g001

DNA methylation patterns in CpG Is of the Shati/Nat8l promoter region in several mouse brain regions

Genomic DNA from three brain regions of mice were isolated and treated with sodium bisulfite, to determine the effect of Meth on DNA methylation in the Shati/Nat8l. The resulting DNA was used for methylation-specific PCR using primers designed to detect the methylation status of Shati/Nat8l CpG Is. Primers for the CpG Is of Shati/Nat8l were designed using Methyl Primer Express (Applied Biosystems,), with the following requirements: %GC >50, CpG Is length: 300~2000 bp, and observed/expected CpG>0.6. According to these requirements, primers for the CpG Is of Shati/Nat8l were placed at −562 and +1342 bp from the transcription start site. Therefore, we attempted to analyze the methylation rate of the promoter region of this area (−562 to −135; 17CpGs). As shown in Fig 2A, the methylation ratio of the DNA extracted from NAc of Meth-treated mice was significantly decreased at −525 bp (saline: 58.33 ± 22.05%, Meth: 11.86 ± 11.55%, p < 0.05), −416 bp (saline: 46.30 ± 11.56%, Meth: 0.00%, p < 0.05), and −409 bp (saline: 43.52 ± 16.28%, Meth: 0.00%, p < 0.05) from the Shati/Nat8l transcription start site compared with saline-treated mice. However, no significant changes in the methylation status of these genomic regions were observed in the HIP and CB of Meth-treated mice (Fig 2Ab and 2Ac).

[Figure omitted. See PDF.]

Fig 2. The methylation profiles of Shati/Nat8l DNA from mouse brain (A) and cardiac blood (B).

The promoter region of Shati/Nat8 was analyzed in DNA collected from (a) nucleus accumbens (NAc), (b) hippocampus (HIP), (c) cerebellum (CB) and (B) cardiac blood (BLD) of mice. The methylation ratios of each CpG unit and the average of the region are represented. Saline and Meth groups are indicated by white and black bars, respectively. Data are plotted as the mean ± SEM. n = 6 mice. Significance is set at *p < 0.05.

https://doi.org/10.1371/journal.pone.0157959.g002

DNA methylation patterns in CpG Is of the Shati/Nat8l promoter region in mouse cardiac blood

Next, genomic DNA from mice cardiac blood was isolated and treated with sodium bisulfite. The DNA was sequenced to determine CpG methylation status in cardiac blood from mice treated with Meth. As shown in Fig 2B, CpG methylation in DNA from cardiac blood was significantly decreased at −525 bp (sSline: 58.33 ± 22.05%, Meth: 11.86 ± 11.55%, p < 0.05) from the Shati/Nat8l transcription start site in mice that were repeatedly treated with Meth compared with saline-treated mice. Table 1 indicates a typical methylation pattern for individual colonies that were derived from independent bisulfite-treated and PCR-amplified genomic DNA samples. The left half shows the methylation patterns of the saline group and the right half represents the methylation patterns of the MAP group. Open and closed circles indicate unmethylated, and methylated sites, respectively.

[Figure omitted. See PDF.]

Table 1. The methylation profiles of Shati/Nat8l DNA of mice blood.

https://doi.org/10.1371/journal.pone.0157959.t001

The methylation pattern is shown for individual colonies that were derived from independent bisulfite-treated and PCR-amplified genomic DNA samples. The left half shows methylation pattern of saline group, and the right half presents one of Meth group. Open circles indicate that the site is unmethylated, and closed circles indicate that a site is methylated. The above numbers are corresponding as below. Vertical axis indicate picked up one colony. The target region consists of 17 CpGs from -533 to -159 nucleotides (CpG1 = -533, CpG2 = -525, CpG3 = -454, CpG4 = -422, CpG5 = -416, CpG6 = -409, CpG7 = -305, CpG8 = -269, CpG9 = -244, CpG10 = -236, CpG11 = -218, CpG12 = -213, CpG13 = -200, CpG14 = -198, CpG15 = -192, CpG16 = -181, CpG17 = -159) upstream from the transcription start site. These were numbered 1–17 in the 5' to 3' direction.

DNA methylation patterns in CpG Is of the SHATI/NAT8L promoter region in human peripheral blood from patients with schizophrenia

Primers for the CpG Is of human SHATI/NAT8l were designed using Methyl Primer Express (Applied Biosystems) with the following requirements: %GC >50, CpG Is length: 300~4000 bp, and observed/expected CpG>0.6. According to this requirement, the CpG Is of human SHATI/NAT8L was defined as −1726 to +2159 bp from the transcription start site. At in silico study, these region include nearly the same transcriptional binding site sequence as in mice -533 to -159 region. Therefore, we attempted to analyze the promoter region of this area (−1714 to −1039 bp; 36CpGs). These sequences are not the same as the mouse alignments; however, they do have the same transcription factor-binding sites as mice. As shown in Table 2, the methylation ratio in peripheral blood was significantly lower at −1532, −1509, −1492, and −1480 bp from the transcription start site in patients with schizophrenia compared with that of healthy controls.

[Figure omitted. See PDF.]

Table 2. The methylation profiles of SHATI/NAT8L DNA from the human blood.

https://doi.org/10.1371/journal.pone.0157959.t002

Discussion

We previously reported that the expression of Shati/Nat8l mRNA was increased in the prefrontal cortex, striatum, and NAc of mice treated with repeated administration of Meth [3]. In addition, we found Shati/Nat8l mRNA in the neuronal cells throughout the specific brain regions of mice using in situ hybridization methods [15]. In this study, we found significant decreases in Shati/Nat8l promoter CpG Is methylation in DNA extracted from both the NAc and blood of Meth-treated mice. In the HIP and CB, differences in methylation status were not observed in Meth-treated mice. In addition, the methylation ratio in the CB and HIP was lower than that in other brain regions, even in comparison to the control group. As shown in Fig 1, Shati/Nat8l mRNA expression was increased in the NAc but not in the HIP or CB of Meth-treated mice. In mouse brain areas where lower levels of methylation in Shati/Nat8l CpG Is was seen, Shati/Nat8l mRNA expression was not affected by the repeated administration of Meth. Thus, additional mechanisms may regulate transcription of Shati/Nat8l.

The reactions that drive demethylation of cytosine residues in DNA can include hydroxymethylation [16, 17]. Therefore, in this study we focused on changes in methylation status in the brain tissue and blood.

Significant changes in both the mRNA expression and the methylation ratio of Shati/Nat8l in the NAc, which receives dopaminergic neuronal input, were observed. Dopaminergic regulations can be influenced by Meth owing to the increase of monoamines uptake and dopamine production [18]. Everitt and colleagues reported that the changes in the expression levels of dopamine receptors and dopamine transporters in the HIP and CB were different from those in the NAc [19]. It is possible that differences in the regulation of the dopaminergic system among the NAc, HIP and CB contribute to the differences in DNA methylation in these regions.

Most neuronal systems in the NAc consist of GABAergic neurons. With respect to GABAergic neurons, DNA methylation of GAD67 and GABA synthetase is greatly altered by maternal restriction stress in the brains of mice as well as in patients with schizophrenia [20, 21]. Taken together, our results along with previous studies suggest that GABAergic neurons may regulate DNA methylation of Shati/Nat8l in response to stress or psychiatric disorder. In this study, the methylation rate of four different CpG Is of Shati/Nat8l were significantly decreased in patients with schizophrenia. Further study is necessary to clarify the relationship of these findings with GAD67.

The systems that regulate DNA methylation consist of many molecules, including DNA methyltransferases (DNMTs) [22], TET methylcytosine dioxygenases [23], methylated DNA-binding protein, and MeCP2 [24]. It has been reported that Tet1-KO animals exhibit abnormal hippocampal long-term depression and impaired memory extinction in addition to downregulation of multiple neuronal activity-regulated genes, including Npas4, c-Fos, and Arc [25]. In a human study, Tet1 mRNA and protein levels were upregulated in the brains of postmortem patients with schizophrenia compared with those of healthy controls. DNMTs are enzymes that cause cytosine methylation, and they have been reported to suppress GAD67 mRNA expression via methylation of the promoter region [26]. Furthermore, DNMT expression was upregulated in the peripheral blood of patients with schizophrenia and in the brains of postmortem patients with schizophrenia [20]. MeCP2 can bind to methylated cytosine bases and act not only to suppress gene expression itself, but it can also recruit other suppressive proteins, and suppress the expression of other genes [27, 28]. Administration of psychostimulant drugs modulates many transcription factors, such as DNMT, MeCP2, and HDAC [29, 30], and these transcription factors show decreased DNA binding ability [31]. 5hmC may be especially important in the central nervous system, as it is found in very high levels there [32]. These reports may support the inconsistent results shown in Fig 2A and 2B, that CpG -525 is significantly hypomethylated in both NAc and blood of Meth-treated mice, but CpG -416 and -409 show no DNA methylation-difference in the blood of Meth-treated mice. In our study, Shati/Nat8l expression in the NAc was upregulated by Meth exposure and was accompanied by suppressed methylation in CpG Is of Shati/Nat8l DNA. Future studies should focus on detailing the mechanisms of this process. In future, we also try other psychiatric disease patients such as bipolar, depression and anxiety.

In this study, we report important findings of the effects of repeated administration of psychostimulant drug on DNA methylation of specific gene not only in the brain but also in peripheral blood of mice. These results were correlated with human studies. Blood tests for the methylation of CpG Is of Shati/Nat8l might be useful as a method for diagnosing patients with schizophrenia in the future

Author Contributions

Conceived and designed the experiments: KU TS AN. Performed the experiments: KU YK MI YO. Analyzed the data: KU YK MI AN. Contributed reagents/materials/analysis tools: KU TU TM TS YO HJ TT YFH TN YM AN. Wrote the paper: KU TS AN.

Citation: Uno K, Kikuchi Y, Iwata M, Uehara T, Matsuoka T, Sumiyoshi T, et al. (2016) Decreased DNA Methylation in the Shati/Nat8l Promoter in Both Patients with Schizophrenia and a Methamphetamine-Induced Murine Model of Schizophrenia-Like Phenotype. PLoS ONE 11(6): e0157959. https://doi.org/10.1371/journal.pone.0157959

References

1. Iwamoto K, Bundo M, Yamada K, Takao H, Iwayama-Shigeno Y, Yoshikawa T, et al. DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. J Neurosci. 2005;25:5376–81. pmid:15930386.

2. Abdolmaleky HM, Smith CL, Zhou JR, Thiagalingam S. Epigenetic alterations of the dopaminergic system in major psychiatric disorders. Methods Mol Biol. 2008;448:187–212. pmid:18370235.

3. Niwa M, Nitta A, Mizoguchi H, Ito Y, Noda Y, Nagai T, Nabeshima T. A novel molecule "shati" is involved in methamphetamine-induced hyperlocomotion, sensitization, and conditioned place preference. J Neurosci. 2007;27:7604–15. pmid:17626222

4. Niwa M, Yan Y, Nabeshima T. Genes and molecules that can potentiate or attenuate psychostimulant dependence: relevance of data from animal models to human addiction. Ann N Y Acad Sci. 2008;1141:76–95. pmid:18991952

5. Miyamoto Y, Ishikawa Y, Iegaki N, Sumi K, Fu K, Sato K, et al. Overexpression of Shati/Nat8l, an N-acetyltransferase, in the nucleus accumbens attenuates the response to methamphetamine via activation of group II mGluRs in mice. Int J Neuropsychopharmacol. 2014;17:1283–94. pmid:24559655

6. Furukawa-Hibi Y, Nitta A, Fukumitsu H, Somiya H, Toriumi K, Furukawa S, et al. Absence of SHATI/NAT8L reduces social interaction in mice. Neurosci Lett. 2012;526:79–84. pmid:22940080

7. Machiyama Y. Chronic methamphetamine intoxication model of schizophrenia in animals. Schizophr Bull. 1992;18:107–13. pmid:1553490

8. Takigawa M, Maeda H, Ueyama K, Tominaga H, Matsumoto K. A dual approach to self-stimulation and locomotor trace affected by chronic methamphetamine treatment for an animal model of schizophrenia. Can J Physiol Pharmacol. 1993;71:321–5. pmid:8402397

9. Yui K, Ikemoto S, Ishiguro T, and Goto K. Studies of amphetamine or methamphetamine psychosis in Japan: relation of methamphetamine psychosis to schizophrenia. Ann NY Acad Sci. 2000;914: 1–12. pmid:11085303.

10. Laird PW, Jaenisch R. The role of DNA methylation in cancer genetic and epigenetics. Annu Rev Genet. 1996;30:441–64. pmid:8982461.

11. Fuchikami M, Morinobu S, Segawa M, Okamoto Y, Yamawaki S, Ozaki N, et al. DNA methylation profiles of the brain-derived neurotrophic factor (BDNF) gene as a potent diagnostic biomarker in major depression. PLoS One. 2011;6: e23881. pmid:21912609.

12. Niwa M, Jaaro-Peled H, Tankou S, Seshadri S, Hikida T, Matsumoto Y, et al. Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids. Science. 2013;339:335–9. pmid:23329051

13. Bird AP. CpG-rich islands and the function of DNA methylation. Nature. 1986; 321:209–13. pmid:2423876.

14. Bird AP. DNA methylation versus gene expression. J Embryol Exp Morphol. 1984;83 S:31–40. pmid:6598198.

15. Sumi K, Uno K, Matsumura S, Miyamoto Y, Furukawa-Hibi Y, Muramatsu S, et al. Induction of neuronal axon outgrowth by Shati/Nat8l by energy metabolism in mice cultured neurons. Neuroreport. 2015;26:740–6. pmid:26164607.

16. Münzel M, Globisch D, Brückl T, Wagner M, Welzmiller V, Michalakis S, et al. Quantification of the sixth DNA base hydroxymethylcytosine in the brain. Angew Chem Int Ed Engl. 2010;49:5375–7. pmid:20583021.

17. Lu K, Craft S, Nakamura J, Moeller BC, Swenberg JA. Use of LC-MS/MS and stable isotopes to differentiate hydroxymethyl and methyl DNA adducts from formaldehyde and nitrosodimethylamine. Chem Res Toxicol. 2012;25:664–75. pmid:22148432.

18. Riddle EL, Fleckenstein AE, Hanson GR. Role of monoamine transporters in mediating psychostimulant effects. AAPS J. 2005;7:E847–51. pmid:16594636.

19. Everitt BJ, Robbin TW. From the ventral to the dorsal striatum: Devolving views of their roles in drug addiction. Neurosci Biobehav Rev. 2013;37:1946–54. pmid:23438892

20. Zhubi A, Veldic M, Puri NV, Kadriu B, Caruncho H, Sershen H, et al. An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. Schizophr Res. 2009;111:115–22. pmid:19386473.

21. Matrisciano F, Tueting P, Dalal I, Kadriu B, Grayson DR, Davis JM, et al. Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology. 2013;68:184–94. pmid:22564440

22. Gruenbaum Y, Cedar H, Razin A. Substrate and sequence specificity of a eukaryotic DNA methylase. Nature. 1982;295:620–2. pmid:7057921.

23. Williams K, Christensen J, Helin K. DNA methylation:TET proteins-guardians of CpG islands? EMBO Rep. 2011;13:28–35. pmid:22157888.

24. Boyes J, Bird A. DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell. 1991;64:1123–34. pmid:2004419.

25. Rudenko A, Dawlaty MM, Seo J, Cheng AW, Meng J, Le T, et al. Tet1 is critical for neuronal activity-regulated gene expression and memory extinction. Neuron. 2013;79:1109–22. pmid:24050401

26. Dong E, Ruzicka WB, Grayson DR, Guidotti A. DNA-methyltransferase1 (DNMT1) binding to CpG rich GABAergic and BDNF promoters is increased in the brain of schizophrenia and bipolar disorder patients. Schizophr Res. 2015;167:35–41. pmid:25476119.

27. Deng JV, Rodriguiz RM, Hutchinson AN, Kim IH, Wetsel WC, West AE. MeCP2 in the nucleus accumbens contributes to neural and behavioral responses to psychostimulants. Nat Neurosci. 2010;13:1128–36. pmid:20711186.

28. Zhong X, Li H, Chang Q. MeCP2 phosphorylation is required for modulating synaptic scaling through mGluR5. J Neurosci. 2012;32:12841–7. pmid:22973007.

29. Jayanthi S, McCoy MT, Chen B, Britt JP, Kourrich S, Yau HJ, et al. Methamphetamine downregulates striatal glutamate receptors via diverse epigenetic mechanisms. Biol Psychiatry. 2014;76:47–56. pmid:24239129

30. Numachi Y, Yoshida S, Yamashita M, Fujiyama K, Naka M, Matsuoka H, et al. Psychostimulant alters expression of DNA methyltransferase mRNA in the rat brain. Ann N Y Acad Sci. 2004;1025:102–9. pmid:15542706.

31. Bednarik DP, Cook JA, Pitha PM. Inactivation of the HIV LTR by DNA CpG methylation: evidence for a role in latency. EMBO J. 1990;9:1157–64. pmid:2323336.

32. Globisch D, Münzel M, Müller M, Michalakis S, Wagner M, Koch S, et al. Tissue Distribution of 5-Hydroxymethylcytosine and Search for Active Demethylation Intermediates. PLoS One. 2010;5:e15367. pmid:21203455